BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearItem 5.03
On November17, 2017, the Board of Directors (the “Board”) of BioDelivery Sciences International, Inc. (the “Company”) adopted the Second Amended and Restated Bylaws of the Company (the “Second Amended Bylaws”). The Second Amended Bylaws became effective on November17, 2017. The only material change to the Second Amended Bylaws compared to the Company’s previous amended and restated bylaws was a change in the threshold of stockholder vote needed at a duly called meeting of stockholders to remove a member of the Board for cause from sixty-six and two-thirds percent (66 2/3%) of the stockholders entitled to vote at such meeting to a majority of the holders of shares entitled to vote at such meeting. This change was made in order for the Company’s bylaws to be in conformance with current Delaware law.
| Item 5.03 | Financial Statements and Exhibits. |
(d) The following exhibit are filed with this report.
BIODELIVERY SCIENCES INTERNATIONAL INC ExhibitEX-3.1 2 d424679dex31.htm EX-3.1 EX-3.1 Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS OF BIODELIVERY SCIENCES INTERNATIONAL,…To view the full exhibit click here
About BioDelivery Sciences International, Inc. (NASDAQ:BDSI)
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company’s products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company’s United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.
